FCM has until recently been predominantly used to phenotype leukemias and lymphomas and to aid in prognosis of nonhematologic tumors. Nonhematologic tumors In nonhematologic tumors, predominately aneuploid neoplasms (especially if the S-phase value is increased) generally are more aggressive and have shorter survival time than tumors that are predominantly diploid and have normal S-phase values. […]